Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation

Clinical Infectious Diseases

Volumn 62, Issue 7, 2016, Pages 951-953

  Mössner, Rotraut ^a   Diering, Nina ^a   Bader, Oliver ^a   Forkel, Susann ^a   Overbeck, Tobias ^a   Gross, Uwe ^a   Grimbacher, Bodo ^b,c   Schön, Michael P ^a   Buhl, Timo ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FILGRASTIM; FLUCYTOSINE; INTERLEUKIN 17; INTERLEUKIN 17F; RUXOLITINIB; STAT1 PROTEIN; PYRAZOLE DERIVATIVE; STAT1 PROTEIN, HUMAN;

DYSPHAGIA; GAIN OF FUNCTION MUTATION; HUMAN; LETTER; MUCOCUTANEOUS CANDIDIASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; CASE REPORT; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MUTATION; PATHOLOGY; TONGUE;

CANDIDIASIS, CHRONIC MUCOCUTANEOUS; HUMANS; INTERLEUKIN-17; MALE; MUTATION; PYRAZOLES; STAT1 TRANSCRIPTION FACTOR; TONGUE;

EID: 84963938592     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw020     Document Type: Letter

References (7)

1. van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011; 365: 54-61.
2. Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011; 208: 1635-48.
3. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011; 332: 65-8.
4. Wildbaum G, Shahar E, Katz R, Karin N, Etzioni A, Pollack S. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol. 2013; 132: 761-4.
5. van de Veerdonk FL, Koenen HJ, van der Velden WJ, van der Meer JW, Netea MG. Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis. Immunol Lett. 2015; 167: 54-6.
6. Higgins E, Al Shehri T, McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015; 135: 551-3.
7. Bader O, Weig MS, Gross U, Schön MP, Mempel M, Buhl T. Photo quiz A 32-year-old man with ulcerative mucositis, skin lesions, and nail dystrophy. Chronic mucocutaneous candidiasis by multidrug-resistant Candida albicans. Clin Infect Dis. 2012; 54: 972, 1035-6.